In this episode, Scott Becker examines GoodRx’s 30% surge after entering the weight loss drug market, the rapid growth of hims and hers, and Novo Nordisk’s move to cut prices on Ozempic as competition in the GLP-1 space intensifies.
No transcript available.
POWERED BY BLUBRRY
